Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Non Operating Income (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Other Non Operating Income readings, the most recent being -$151000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Other Non Operating Income rose 91.44% year-over-year to -$151000.0, compared with a TTM value of -$133000.0 through Dec 2025, up 93.87%, and an annual FY2025 reading of -$133000.0, up 93.87% over the prior year.
  • Other Non Operating Income hit -$151000.0 in Q4 2025 for Apellis Pharmaceuticals, down from $37000.0 in the prior quarter.
  • The five-year high for Other Non Operating Income was $43.8 million in Q4 2021, with the low at -$21.2 million in Q2 2021.
  • Median Other Non Operating Income over the past 5 years was -$134000.0 (2021), compared with a mean of $107500.0.
  • The sharpest move saw Other Non Operating Income soared 8782.18% in 2021, then plummeted 905.94% in 2024.
  • Year by year, Other Non Operating Income stood at $43.8 million in 2021, then crashed by 100.56% to -$246000.0 in 2022, then surged by 189.02% to $219000.0 in 2023, then crashed by 905.94% to -$1.8 million in 2024, then skyrocketed by 91.44% to -$151000.0 in 2025.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at -$151000.0, $37000.0, and $146000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.